{
  "id": 3380475,
  "title": "Ceribell (CBLL) CRO Joseph Manni sells $32,691 in shares",
  "url": "https://urgent.news/2026/08/26/ceribell-cbll-cro-joseph-manni-sells-32-691-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-26T00:01:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/ceribell-cbll-cro-joseph-manni-sells-32691-in-shares-93CH-4876073"
  },
  "original_language": "en",
  "account": "Chief Revenue Officer Joseph S. Manni of Ceribell, Inc. (CBLL) divested 1,361 shares of the company's stock on August 21, 2026, for a total of $32,691. The shares were sold at $24.02 per share, coinciding with Ceribell's stock trading near its 52-week high of $25.33, which represents a 109% return over the past year. The transaction was executed to satisfy tax withholding requirements related to the vesting of restricted stock units. Post-sale, Manni now directly owns 55,956 shares of Ceribell common stock, including 1,026 shares acquired through the company’s Employee Stock Purchase Plan on July 31, 2026. While Ceribell boasts a robust balance sheet with more cash than debt and impressive gross profit margins of 88.9%, InvestingPro analysts indicate the stock might be overvalued at the current level. Interested investors can access a comprehensive Pro Research Report on Ceribell among 1,400+ reports available on InvestingPro. Ceribell reported robust financial results for the second quarter of fiscal 2026, with revenue increasing by 33% to $28.1 million compared to the prior year. Although the company reported a loss of $0.51 per share, which exceeded the expected $0.36 loss, its expansion in seizure-detection technology, new products for delirium monitoring, and pediatric care has garnered investor interest. Following the earnings report, Canaccord raised its price target for Ceribell to $26 from $25 and maintained a Buy rating, citing the company's strong same-store utilization and recent account additions. BTIG also increased its price target to $30 from $28, highlighting Ceribell's growth outlook and leadership in point-of-care rapid EEG technology. Both analysts have reaffirmed their Buy ratings, underscoring confidence in Ceribell's market position and future potential. This report was AI-generated and reviewed by an editor.",
  "summary": null,
  "key_points": [
    "Joseph Manni sold 1,361 shares of Ceribell stock for $32,691 on August 21, 2026.",
    "Shares were sold at $24.02 each, near Ceribell's 52-week high of $25.33.",
    "Manni now owns 55,956 shares, including 1,026 from the Employee Stock Purchase Plan."
  ],
  "editors_take": "The sale of shares by Ceribell's Chief Revenue Officer to satisfy tax withholding requirements does not seem to have dented analyst confidence, with Canaccord and BTIG reaffirming their Buy ratings and raising price targets.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Ardelyx SVP Joseph Reilly sells $15,358 of company stock",
        "url": "https://urgent.news/2026/08/25/ardelyx-svp-joseph-reilly-sells-15-358-of-company-stock",
        "published": "2026-08-25T23:50:04.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}